Phase 2 results demonstrate rilzabrutinib
Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous ...
Read morePhase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous ...
Read moreInnovative oral care solution aims to benefit patients taking blood thinning medications, who have an increased risk of prolonged bleeding ...
Read moreThe new ball will feature on pitch for the first time during the first leg of the Quarter Final matches ...
Read moreLAS VEGAS, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via IBN -- Golden Triangle Ventures, Inc. (OTC PINK: GTVH) (“GTV” or ...
Read moreOver 40 sites (U.S. and Canada) have agreed to participate in the LEVEL study LEVEL is a randomized, controlled Phase ...
Read moreHONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; ...
Read more51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid) ...
Read moreORION CORPORATION PRESS RELEASE 26 JANUARY 2024 at 09.00 EET Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024Orion presented yesterday ...
Read moreCopenhagen, Denmark, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Meta: Genixor is thrilled to announce the commencement of its second phase ...
Read morePRESS RELEASE BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.